- Q3 2023 Immunic Inc Earnings Call TranscriptNov 14, 2023$0.9902 (+2.16%)Earnings
- Immunic Inc To Discuss Interim Data Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive MS Call TranscriptOct 10, 2023
- Q2 2023 Immunic Inc Earnings Call TranscriptAug 03, 2023$2.13 (-1.39%)Earnings
- Immunic Inc To Host Key Opinion Leaders TranscriptJul 20, 2023
- Q1 2023 Immunic Inc Earnings Call TranscriptMay 11, 2023$1.82 (+1.68%)Earnings
- Immunic Inc To Discuss IMU-856 Clinical Phase 1b Results in Celiac Disease Call TranscriptMay 04, 2023
- Immunic Inc To Discuss Phase 2b CALDOSE-1 Maintenance Phase Data Call TranscriptApr 05, 2023
- Q4 2022 Immunic Inc Earnings Call TranscriptFeb 23, 2023$1.97 (+4.23%)Earnings
- Immunic Inc Celiac Disease R&D Webcast TranscriptFeb 09, 2023
- Immunic Inc Corporate Call TranscriptNov 17, 2022
- Q3 2022 Immunic Inc Earnings Call TranscriptNov 03, 2022$1.58 (-7.60%)Earnings
- Immunic Inc Webinar: IMU-856 Phase 1 SAD/MAD Data in Healthy Human Subjects TranscriptSep 20, 2022
- Q2 2022 Immunic Inc Earnings Call TranscriptAug 04, 2022$4.79 (+23.14%)Earnings
- Immunic Inc Corporate Update TranscriptJun 02, 2022
- Q1 2022 Immunic Inc Earnings Call TranscriptMay 10, 2022$5.5 (+5.36%)Earnings
- Q4 2021 Immunic Inc Earnings Call TranscriptFeb 24, 2022$10.72 (-9.15%)Earnings
- Q3 2021 Immunic Inc Earnings Call TranscriptNov 04, 2021$10.25 (+2.60%)Earnings
- Immunic Inc Discuss Overall MS Development Strategy - Corporate Call TranscriptJul 01, 2021
- Q2 2020 Immunic Inc Earnings Call TranscriptAug 03, 2020Earnings
Q2 2020 Immunic Inc Earnings Call Transcript
Hello, and welcome to Immunic Therapeutics conference call. (Operator Instructions) Please note, today's event is being recorded.
I would now like to turn the conference over to Jessica Breu. Ms. Breu, please go ahead.
Yes. Thank you, Keith. Good morning, and welcome to Immunic's conference call and webcast to discuss yesterday's press release regarding the positive top line data from our Phase II EMPhASIS trial of IMU-838 in relapsing-remitting multiple sclerosis, which we are very excited about and which we want to share with you on today's call.
My name is Jessica Breu, Head of Investor Relations and Communications at Immunic. Speaking on today's call are with me Dr. Daniel Vitt, our Chief Executive Officer and President; and Dr. Andreas Muehler, our Chief Medical Officer.
Before we begin, I would like to remind you that this webcast may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimates or
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)